Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic Leukemia
- 1 May 2009
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (3) , 201-210
- https://doi.org/10.2353/jmoldx.2009.080048
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic LeukemiaThe Journal of Molecular Diagnostics, 2009
- Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-κ and heavy-chain gene rearrangementsLeukemia, 2008
- Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoringLeukemia, 2007
- Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subcloneBlood, 2007
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingLeukemia, 2007
- Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemiaBritish Journal of Haematology, 2006
- Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapyLeukemia, 2001
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Monitoring minimal residual disease in peripheral blood in B‐lineage acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997